Kiniksa Pharmaceuticals International, plc (KNSA): Cash & Equivalents
$165.60M
As of 2025-12-31
$189.95M
As of 2026-03-31
+10.5%
3-year compound annual growth
+7.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $165.60M | -9.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $183.58M | +70.1% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $107.95M | -12.0% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $122.72M | +0.2% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $122.47M | +7.4% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $114.04M | +143.0% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $46.93M | -34.8% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $71.98M | +58.0% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $45.55M | n/a | 2019-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $79.15M | -56.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗